Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute myeloid leukaemia

R F Stevens1

  • 1Royal Manchester Children's Hospital, Manchester, UK.

British Medical Bulletin
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Significant advancements in treating childhood acute myeloid leukaemia (AML) have been made. Genetic insights enable better diagnosis of this heterogeneous disease, guiding future collaborative treatment protocols for better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.

Leukemia·2005
Same author

Guidelines for the diagnosis and management of hereditary spherocytosis.

British journal of haematology·2004
Same author

Childhood linear IgA disease in association with autoimmune lymphoproliferative syndrome.

The British journal of dermatology·2004
Same author

Association of acute parvovirus B19 infection with new onset of acute lymphoblastic and myeloblastic leukaemia.

Journal of clinical pathology·2003
Same author

A unique variant of ETV6/AML1 fusion in a child with acute lymphoblastic leukemia.

Leukemia·2003
Same author

Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.

Leukemia·2002
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
Same journal

Enhancing bone healing through osteogenic medium components: biological roles, mechanisms, and clinical applications.

British medical bulletin·2026
Same journal

Moral injury in healthcare workers: causes & interventions.

British medical bulletin·2026
See all related articles

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Cancer Genetics

Background:

  • Childhood acute myeloid leukaemia (AML) is a heterogeneous disease with evolving treatment strategies.
  • Progress in understanding AML has been driven by advancements in cyto- and molecular genetics.
  • Current treatments rely on cytotoxic chemotherapy and bone marrow transplantation.

Purpose of the Study:

  • To highlight progress in childhood acute myeloid leukaemia (AML) understanding and treatment.
  • To emphasize the role of genetics in diagnosing heterogeneous AML.
  • To propose a collaborative approach for future therapeutic trials.

Main Methods:

  • Review of progress in childhood acute myeloid leukaemia (AML) over the past two decades.
  • Analysis of the impact of genetic diagnostics on AML classification.

Related Experiment Videos

  • Discussion of current treatment modalities including chemotherapy and bone marrow transplantation.

    • Main Results:

    • Genetic advancements allow for more specific diagnosis of heterogeneous childhood acute myeloid leukaemia (AML).
    • Treatment has progressed through increased use of chemotherapy and bone marrow transplantation.
    • Randomized therapeutic trials for rare diseases like AML are challenging.

    Conclusions:

    • Collaborative international efforts among pediatric trial groups are essential.
    • Developing common or parallel therapeutic protocols will advance AML treatment.
    • Genetics plays a crucial role in refining diagnosis and treatment strategies for childhood AML.